Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
Retina Vitreous Associates Medical Group, Los Angeles, California Mayo Clinic, Rochester, Minnesota Retina Consultants of Texas, Bellaire, Texas Retina Foundation of the Southwest, Dallas, Texas United Kingdom
Moorfields Eye Hospital NHS Foundation Trust, London, England The Retina Clinic, London, England